“Global Biologics market set to grow to $250bn by 2023” says Visiongain

14 November 2018
Pharma

Visiongain has launched a new pharma report: Biologics Market Trends and Forecasts 2018-2028: Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

Bio therapeutics is the fastest-growing sector in the pharmaceutical industry, with total revenues reaching up to $163 billion. Its annual growth surpasses 8%, whereas conventional pharmaceuticals barely reach 4%. The current landscape of biologics promises continuous growth. Biologics are much costlier than small molecule drugs, these classes of drugs bring about 40% higher profit to the manufacturers when compared to small molecule drugs. Additionally, the growing demand for biologics drugs coupled with the increased regulatory approvals for these drugs will increase the demand for biologics manufacturing and testing at various levels of clinical studies as well as commercial supply.

The lead analyst of the report commented "The biologics market is built on technological innovation and continued development of biotechnology is the key to the market’s future. The tools for innovation as well as for manufacturing are becoming widely disseminated. The suite of techniques that stand behind the current mAbs market, including phage display, humanisation and transgenic mice, are now off-patent and available to any company that wishes to take advantage of them.

Therefore, there is a major need for new platforms that can keep new and emerging technologies in the hands of innovator companies. Rapid advances in assays will also have a major knock-on effect on the biopharmaceutical industry, both by permitting more rapid and accurate characterisation of biologics and biosimilars, and by allowing new diagnostic tools into the market. New diagnostics will accelerate the rise of personalised medicine, which is likely to be highly relevant to the future of the biologics market."

Leading companies featured in the report include AbbVie, Amgen, AstraZeneca, Bayer, Eli Lilly, Roche, GlaxoSmithKline (GSK), Johnson & Johnson, Merck & Co., Inc., Novartis, Pfizer, Sanofi S.A.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

Read

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

Read

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever